Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

194.29 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 203
Open 194.29
Bid (Size) 193.56 (1)
Ask (Size) 194.33 (1)
Prev. Close 194.29
Today's Range 194.29 - 194.29
52wk Range 135.85 - 199.95
Shares Outstanding N/A
Dividend Yield 3.05%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Magnificent Dividend Stocks to Buy in October
These dividend stocks are great picks as the fall season gets underway. 
Via The Motley Fool
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?
Declining earnings haven't scared billionaire investors away from this stock. 
Via The Motley Fool

Performance

YTD
+21.57%
+21.57%
1 Month
+0.46%
+0.46%
3 Month
+16.68%
+16.68%
6 Month
+14.42%
+14.42%
1 Year
+30.30%
+30.30%

More News

Read More
2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now
Via The Motley Fool
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Comparing AbbVie With Industry Competitors In Biotechnology Industry
Via Benzinga
Behind the Scenes of AbbVie's Latest Options Trends
Via Benzinga
(ABBV) - Analyzing AbbVie's Short Interest
Via Benzinga
3 Industries Set To Explode When Interest Rates Drop
Via Talk Markets
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
Via Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Via Benzinga
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
5 Best Dividend Growth Stocks to Buy in October
Via The Motley Fool
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
Behind the Scenes of AbbVie's Latest Options Trends
Via Benzinga
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Via Benzinga
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via FinancialNewsMedia
Meta, Accenture, Disney And A Major Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
Via Benzinga
15 Best Dividend Stocks for Lifelong Passive Income
Via The Motley Fool
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Via Benzinga
Exposures Product Safety
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
Via Benzinga
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
Via The Motley Fool
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Via Benzinga
Exposures Product Safety
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.